Leerink Partnrs Has Bearish Outlook for IDYA FY2026 Earnings

Key Points

• Leerink Partners has decreased its FY2026 earnings per share estimate for IDEAYA Biosciences from ($3.88) to ($4.05), indicating a more pessimistic outlook for the company's financial performance.
• The company reported a quarterly earnings per share of ($0.88), which missed analyst expectations of ($0.85), although it achieved higher revenue of $6 million compared to the $3.48 million expected.
• Despite the negative earnings outlook, multiple analysts have issued "buy" ratings for IDEAYA, with price targets ranging around $38 to $44, reflecting a generally optimistic view among market experts.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Equities research analysts at Leerink Partnrs reduced their FY2026 EPS estimates for shares of IDEAYA Biosciences in a research report issued on Tuesday, September 9th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($4.05) per share for the year, down from their prior estimate of ($3.88). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences' FY2027 earnings at ($4.04) EPS.

A number of other analysts also recently weighed in on the stock. Barclays initiated coverage on shares of IDEAYA Biosciences in a report on Thursday, September 4th. They issued an "overweight" rating and a $40.00 target price on the stock. Royal Bank Of Canada boosted their target price on shares of IDEAYA Biosciences from $36.00 to $38.00 and gave the stock an "outperform" rating in a report on Tuesday, September 9th. Wells Fargo & Company initiated coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 target price on the stock. TD Cowen initiated coverage on shares of IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a "buy" rating on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $42.85.

IDEAYA Biosciences Stock Up 1.6%

NASDAQ IDYA traded up $0.39 on Thursday, reaching $24.92. The company had a trading volume of 348,107 shares, compared to its average volume of 1,152,493. The stock has a market capitalization of $2.18 billion, a PE ratio of -6.57 and a beta of 0.12. The firm's 50 day moving average price is $24.01 and its 200 day moving average price is $20.78. IDEAYA Biosciences has a 12 month low of $13.45 and a 12 month high of $37.19.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to the consensus estimate of $3.48 million. The business's revenue was up NaN% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.68) EPS.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Daiwa Securities Group Inc. lifted its position in IDEAYA Biosciences by 16.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company's stock valued at $66,000 after acquiring an additional 436 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of IDEAYA Biosciences by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company's stock worth $123,000 after acquiring an additional 627 shares during the period. CWM LLC increased its stake in shares of IDEAYA Biosciences by 33.0% in the second quarter. CWM LLC now owns 3,153 shares of the company's stock worth $66,000 after acquiring an additional 782 shares during the period. E Fund Management Co. Ltd. increased its stake in shares of IDEAYA Biosciences by 7.8% in the second quarter. E Fund Management Co. Ltd. now owns 12,225 shares of the company's stock worth $257,000 after acquiring an additional 881 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in shares of IDEAYA Biosciences by 39.1% in the second quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company's stock worth $70,000 after acquiring an additional 940 shares during the period. Hedge funds and other institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.